Get the Stockscreener App
13.64
1.87%
0.25
Mind Medicine Inc stock is traded at $13.64, with a volume of 1.66M.
It is up +1.87% in the last 24 hours and up +13.10% over the past month.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).
See More
Previous Close:
$13.39
Open:
$13.5
24h Volume:
1.66M
Relative Volume:
0.85
Market Cap:
$1.34B
Revenue:
$11.40B
Net Income/Loss:
$-95.73M
P/E Ratio:
-5.5673
EPS:
-2.45
Net Cash Flow:
$-64.37M
1W Performance:
+4.44%
1M Performance:
+13.10%
6M Performance:
+92.66%
1Y Performance:
+80.90%
1-Day Range:
$13.24
$13.67
1-Week Range:
$12.85
$13.67
52-Week Range:
$4.70
$14.43
Mind Medicine Inc Stock (MNMD) Company Profile
Name
Mind Medicine Inc
Sector
Industry
Phone
212-220-6633
Address
ONE WORLD TRADE CENTER, NEW YORK
Compare MNMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MNMD
Mind Medicine Inc
|
13.64 | 1.32B | 11.40B | -95.73M | -64.37M | -2.45 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Mind Medicine Inc Stock (MNMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-13-25 | Initiated | Needham | Buy |
| Aug-04-25 | Resumed | Oppenheimer | Outperform |
| Jan-28-25 | Initiated | Evercore ISI | Outperform |
| Dec-20-24 | Initiated | Chardan Capital Markets | Buy |
| Oct-14-24 | Resumed | Leerink Partners | Outperform |
| Jul-24-24 | Initiated | ROTH MKM | Buy |
| May-29-24 | Initiated | Robert W. Baird | Outperform |
| Apr-15-24 | Initiated | Leerink Partners | Outperform |
| Dec-05-23 | Initiated | Canaccord Genuity | Buy |
| Dec-09-22 | Resumed | ROTH Capital | Buy |
| Nov-16-22 | Initiated | RBC Capital Mkts | Outperform |
| Aug-26-22 | Initiated | Oppenheimer | Outperform |
| Aug-10-22 | Initiated | Cantor Fitzgerald | Overweight |
| May-04-22 | Initiated | ROTH Capital | Buy |
| Jun-28-21 | Initiated | Maxim Group | Buy |
View All
Mind Medicine Inc Stock (MNMD) Latest News
Is Mind Medicine MindMed Inc a good long term investmentTrendline Breakouts & Low Cost Portfolio Growth - earlytimes.in
Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (CORT) and Mind Medicine (MNMD) - The Globe and Mail
Mind Medicine (MindMed) (NASDAQ:MNMD) Trading Down 3.8% on Insider Selling - MarketBeat
Mind Medicine (MindMed) (NASDAQ:MNMD) Insider Daniel Karlin Sells 5,600 Shares - MarketBeat
Mind Medicine (MindMed) (NASDAQ:MNMD) CEO Sells $339,151.65 in Stock - MarketBeat
MNMD Stock Up More Than 100% in 6 Months: What's in Store for 2026? - Finviz
Mind Medicine (MindMed) (NASDAQ:MNMD) Shares Up 3.1%Should You Buy? - MarketBeat
Will Mind Medicine (MindMed) Inc. (MMQ) stock sustain uptrend momentumFundamental Stock Analysis & Minimal Investment Trading Plans - bollywoodhelpline.com
What’s driving JonesTrading’s bullish view on Mind Medicine (MindMed) Inc. (MNMD) - MSN
Aug Momentum: Is Mind Medicine MindMed Inc stock a safe investment in uncertain markets2025 Risk Factors & Verified Short-Term Plans - moha.gov.vn
What’s Driving JonesTrading’s Bullish View on Mind Medicine (MindMed) Inc. (MNMD) - Insider Monkey
MindMed Expands Into Autism: What Investors Should Know About the New MM402 Trial - TipRanks
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Receives Average Rating of "Buy" from Analysts - MarketBeat
Palmetto Grain Brokerage - Palmetto Grain Brokerage
Is MindMed (MNMD) Turning Psychedelic Policy Tailwinds Into a Durable Neuropsychiatry Advantage? - Sahm
Wall Street Thinks This 1 Psychedelic Stock Can Gain 335% in 2026 - Yahoo Finance
Trading Systems Reacting to (MNMD) Volatility - Stock Traders Daily
Mind Medicine (MindMed) (NASDAQ:MNMD) Shares Down 4.3%Here's What Happened - MarketBeat
Psychedelics Break Out Of The Fringe Under RFK Jr’s 2025 Reset — But Did MNMD Or CMPS Own The Year? - Stocktwits
Jones Trading Initiates Coverage of Mind Medicine (MNMD) with Buy Recommendation - Nasdaq
Jones Trading initiates coverage of Mind Medicine (MNMD) with buy recommendation - MSN
Jones Trading Initiates Coverage on Mind Medicine (MNMD) with 'B - GuruFocus
Jones Trading initiates coverage on MindMed stock with Buy rating By Investing.com - Investing.com South Africa
Mind Medicine (MindMed) (NASDAQ:MNMD) Shares Gap UpTime to Buy? - MarketBeat
MindMed a new buy at Jones on promise of psychedelics for mental illnesses - Seeking Alpha
Jones Trading Begins Coverage on Mind Medicine (MindMed) (NASDAQ:MNMD) - MarketBeat
Jones Trading initiates coverage on MindMed stock with Buy rating - Investing.com
Mind Medicine (MNMD) Receives a Rating Update from a Top Analyst - The Globe and Mail
Mind Medicine Inc Stock Intrinsic Values - GuruFocus
Mind Medicine (FRA:MMQ) EV-to-OCF : -9.03 (As of Dec. 21, 2025) - GuruFocus
New Highs: Will Mind Medicine (MindMed) Inc. (MMQ) stock sustain uptrend momentumJuly 2025 Setups & Verified Entry Point Detection - Улправда
Is Mind Medicine (MindMed) Inc. stock oversold or undervalued - Улправда
How Mind Medicine (MindMed) Inc. stock benefits from tech adoptionWeekly Trend Report & Technical Pattern Based Signals - Улправда
Psychedelics stocks could benefit from marijuana rescheduling: Jefferies - Seeking Alpha
Can Mind Medicine (MindMed) Inc. stock surprise with earnings upsideQuarterly Performance Summary & High Win Rate Trade Tips - DonanımHaber
Assessing Mind Medicine (MNMD)’s Valuation After Strong Multi‑Year Share Price Gains - Yahoo Finance
Nasdaq Moves: What makes Mind Medicine (MindMed) Inc. stock attractive to growth fundsJuly 2025 Trends & Long-Term Growth Stock Strategies - moha.gov.vn
Assessing Mind Medicine (MNMD)’s Valuation After a Strong Recent Share Price Rally - Sahm
MindMed to Present at the 44th Annual J.P. Morgan Healthcare Conference - Business Wire
RSI Check: Is Mind Medicine (MindMed) Inc. stock oversold or undervalued2025 Sector Review & Trade Opportunity Analysis - Улправда
5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026 - Finviz
MindMed Announces New Employee Inducement Grant - Business Wire
Mind Medicine (HAM:MMQ) EV-to-FCF : -8.89 (As of Dec. 13, 2025) - GuruFocus
Avoiding Lag: Real-Time Signals in (MNMD) Movement - news.stocktradersdaily.com
MindMed Secures $259 Million in Public Offering to Advance Brain Health Innovations - MSN
Stempoint Capital LP Makes New $590,000 Investment in Mind Medicine (MindMed) Inc. $MNMD - MarketBeat
Diadema Partners LP Makes New Investment in Mind Medicine (MindMed) Inc. $MNMD - MarketBeat
Mind Medicine (MindMed) (NASDAQ:MNMD) Shares Down 4.6%Here's Why - MarketBeat
MindMed stock soars 73% after InvestingPro’s undervalued call in May 2024 By Investing.com - Investing.com
Marshall Wace LLP Has $22.20 Million Holdings in Mind Medicine (MindMed) Inc. $MNMD - MarketBeat
Mind Medicine Inc Stock (MNMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Mind Medicine Inc Stock (MNMD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Barrow Robert | Chief Executive Officer |
Dec 26 '25 |
Sale |
13.15 |
25,791 |
339,072 |
778,477 |
| Sullivan Mark | Chief Legal Officer |
Dec 26 '25 |
Sale |
13.15 |
11,276 |
148,244 |
282,576 |
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):